Upstream & Downstream Processing

Thermo says Chinese Gov policy will drive growth

Thermo Fisher Scientific says Chinese Government support for biopharma will help grow its business in the country. The life science services, tools and technology firm saw full-year revenue increase 5% to $25.54 billion in 2019 according to documents filed with the US SEC last week. The contribution from Thermo’s operations in China increased 13% year-on-year. And China was a major topic of discussion for CEO Marc Casper during Thermo’s fourth quarter call. “Government priorities in China are aligned with the…

Sartorius ready to snap up more Danaher and GE’s assets, if required

Sartorius is poised to further expand its life science portfolio to help facilitate the Danaher and GE Healthcare merger if antitrust authorities deem more divestments necessary. In February 2019, Danaher entered an agreement to acquire the BioPharma portion of GE Healthcare’s Life Sciences business for $21.4 billion (€19.4 billion). Nearly a year on and the deal is yet to have been approved by antitrust regulators. Danaher has had to divest various life science assets to help ease the merger, with…

Repligen fighting fit in $10bn bioprocess sector, eyes CGT for growth

Repligen says planned tech launches and growing cell and gene therapy sector demand will drive market expansion and growth in 2020. The bioprocess and life science tech supplier shared its thoughts at the JP Morgan Healthcare conference. CEO Tony Hunt said a “surge” in clinical activity is driving expansion in the CDMO space – citing announcements by Catalent and Thermo Fisher Scientific – and at large pharma firms like Amgen, Novartis and BeiGene. “If you go back a few years…

Ori: ‘Partnerships key to bring down cell therapy COGS’

Ori Biotech estimates its automated and closed manufacturing platform can reduce COGS for autologous cell therapies by 60-80% and has teamed with HCATS to help take it to the clinic. One of the key takeaways from this year’s Phacilitate conference last week was the need for partnerships and collaboration to overcome the many issues currently plaguing the cell and gene therapy space, and specifically manufacturing. One such collaboration is between Hitachi Chemical Advanced Therapeutics Solutions (HCATS), the contract development and…

Tech JV will help cell and gene therapy firms commercialize, say founders

Bio-Techne, Fresenius Kabi, and Wilson Wolf have partnered to cell and gene therapy developers commercialize their products. The joint venture – ownership of which will be split equally – will offer scalable manufacturing technologies and process development know-how to biopharmaceutical developers on a contractual basis. Specifically, Wilson Wolf will contribute its G-Rex cell therapy generation platform, while Bio-Techne will provide its range of proteins, reagents, media, and gene-editing technologies. Fresenius Kabi’s Lovo cell processing system will be available to developers…

GE Healthcare building Swiss cell processing kit plant

GE Healthcare Life Sciences says a single-use kit plant it is building in Grens, Switzerland will serve cell and gene therapy firms in the EU and beyond. The 7,360 square meter facility will be located in Grens near the French border. According to GE Life Sciences the facility will meet global regulatory requirements. A spokesperson told us: “The new site will manufacture the single use kits for Sepax and Sefia cell processing systems and will allow us to increase our…

Astrea arises from the Prometic ashes; inks column deal with Thermo

Astrea Bioseparations will supply prepacked chromatography columns to Thermo Fisher. Formerly known as Prometic Bioseparations, the firm now forms part of KKR life sciences tool platform Gamma Biosciences. Late last year, Bioprocess Insider reported the planned acquisition of Liminal BioSciences’ chromatography and bioprocessing business Prometic Bioseparations by investment firm KKR in a deal worth up to £77 million ($100 million). Now complete, KKR has announced the firm will now be known as Astrea Bioseparations Ltd and is the first company…

Waters adding automation lab tech by buying Andrew Alliance

Waters Corporation will add an automated software system and robotics technology through the acquisition of Swiss biotech firm Andrew Alliance. Life sciences chromatography and measurement company Waters Corporation has not divulged the financial details of the deal, but a company spokesman said it significantly bolsters its lab tech portfolio through the addition of automated technologies. “Andrew Alliance’s cloud-native software platform and user interface dramatically improves the use of automation technology, enabling more scientists to realize the advantages of repeatability and…

UMass Lowell opens pilot freeze-drying development lab

UMass Lowell has opened a lyophilization testing facility where researchers and biopharma can develop freeze-drying processes in a non GMP environment. The facility – dubbed LyoBay – is located in the Mark and Elisia Saab Emerging Technologies and Innovation Center at UMass Lowell, which is located northwest of Boston. It is intended as a development space for scientists and biopharmaceutical companies according to executive director, Karen Hamlin. “The LyoBay offers users the opportunity to take their product technology from the…

iBio aims to cut manufacturing costs and improve data management with AI

iBio will use blockchain tech to cut costs and improve traceability in a deal that may also see Mateon spin-out a biopharma AI specialist. Plant-based biologics CDMO iBio asked EdgePoint AI – a unit of Mateon Therapeutics – to install artificial intelligence (AI) technologies at its manufacturing facility in Bryan, Texas. The idea is that the systems – known as TrustPoint Vision Fabric and TrustPoint Smart Protocols – will monitor production operations conducted and store data in a “blockchain.” Cost savings…